JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Prof Yi-Long Wu speaks to ecancer about a phase 2 study of JS207 plus chemotherapy in patients with unresectable stage III NSCLC.

JS207, a bispecific antibody targeting PD-1 and VEGF, combined with platinum-based chemotherapy shows encouraging activity in patients with unresectable stage III NSCLC.

In this phase II study, 22 of 42 patients underwent surgery following neoadjuvant treatment, with a pathological complete response rate of 54.5% and a major pathological response rate of 72.7%.

Prof Wu further covers the safety profile of the combination. He notes that anaemia and reductions in neutrophil and white blood cell counts among the most common adverse events.